JNJ-28312141

CAS: 885692-52-4

Rif. 3D-KKB69252

Informazioni sul prodotto

• Nome: JNJ-28312141
• Marchio: Biosynth

Descrizione

JNJ-28312141 is a potent, selective inhibitor of the receptor tyrosine kinase TIE2 for the treatment of malignant glioma. It has been shown to inhibit tumor growth and induce cell death in vivo in a number of preclinical models of cancer. JNJ-28312141 also inhibits angiogenesis and reduces inflammatory responses in tumor microenvironments. This drug binds to a unique site on TIE2 that is distinct from the binding site for zoledronate, which is used as an anti-angiogenic therapy. Treatment with JNJ-28312141 has been shown to have positive effects in animal models of bone lesions with mesenchymal markers, including assays that are based on kinase selectivity, growth factor receptor activation, or bone metabolism. The efficacy of JNJ-28312141 has been demonstrated in glioma patients who were undergoing surgery and had resection.
END>

Proprietà chimiche

• Peso molecolare: 460.57 g/mol
• Formula: C₂₆H₃₂N₆O₂
• Purezza: Min. 95%